US20030199521A1 - Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection - Google Patents
Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection Download PDFInfo
- Publication number
- US20030199521A1 US20030199521A1 US10/044,315 US4431502A US2003199521A1 US 20030199521 A1 US20030199521 A1 US 20030199521A1 US 4431502 A US4431502 A US 4431502A US 2003199521 A1 US2003199521 A1 US 2003199521A1
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- formula
- group
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 206
- 238000000034 method Methods 0.000 title claims abstract description 83
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 title claims description 85
- 239000000203 mixture Substances 0.000 title claims description 59
- 208000015181 infectious disease Diseases 0.000 title claims description 41
- 241000711549 Hepacivirus C Species 0.000 title description 38
- 241000700605 Viruses Species 0.000 claims abstract description 33
- 241000710781 Flaviviridae Species 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 81
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 241000283690 Bos taurus Species 0.000 claims description 23
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 16
- 210000001161 mammalian embryo Anatomy 0.000 claims description 16
- 150000001350 alkyl halides Chemical class 0.000 claims description 15
- 150000001409 amidines Chemical class 0.000 claims description 14
- 150000004820 halides Chemical class 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 13
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 68
- 239000007787 solid Substances 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 238000005160 1H NMR spectroscopy Methods 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 28
- 230000000840 anti-viral effect Effects 0.000 description 28
- 0 ***/*1=C(\C2=*(*)C=C*2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=*(*)C=C*2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=CC=C(C)C=C2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=CC=C(C)C=C2)*(**)C2=C1C=CC=C2.**1=C*C=C1.**1=C*C=C1.**1=C*C=C1.**1=C*C=C1.*C.*C.*C.*C.*C.*C.*C.CC1=CC=CC=C1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.[1*]C.[1*]C.[1*]C.[1*]C.[2*]C.[2*]C.[2*]C.[2*]C.[2*]C.[2*]C.[3*]C.[3*]C.[3*]C.[3*]C.[3*]C.[3*]C.[4*]C.[4*]C.[4*]C.[4*]C.[4*]C Chemical compound ***/*1=C(\C2=*(*)C=C*2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=*(*)C=C*2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=CC=C(C)C=C2)*(**)C2=C1C=CC=C2.***/*1=C(\C2=CC=C(C)C=C2)*(**)C2=C1C=CC=C2.**1=C*C=C1.**1=C*C=C1.**1=C*C=C1.**1=C*C=C1.*C.*C.*C.*C.*C.*C.*C.CC1=CC=CC=C1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.[1*]C.[1*]C.[1*]C.[1*]C.[2*]C.[2*]C.[2*]C.[2*]C.[2*]C.[2*]C.[3*]C.[3*]C.[3*]C.[3*]C.[3*]C.[3*]C.[4*]C.[4*]C.[4*]C.[4*]C.[4*]C 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 23
- 238000009472 formulation Methods 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 210000002257 embryonic structure Anatomy 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 239000000725 suspension Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000003359 percent control normalization Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 9
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 239000013592 cell lysate Substances 0.000 description 8
- 210000001771 cumulus cell Anatomy 0.000 description 8
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 8
- -1 for example Chemical group 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229940005561 1,4-benzoquinone Drugs 0.000 description 4
- KOFVLPOSCTWTOE-UHFFFAOYSA-N CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)O1 Chemical compound CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)O1 KOFVLPOSCTWTOE-UHFFFAOYSA-N 0.000 description 4
- CQIACFJXPBKTCI-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CC=C(C3=C(C(F)(F)F)C=C(NC(=N)N)C=C3)O2)C(C(F)(F)F)=C1 Chemical compound N=C(N)NC1=CC=C(C2=CC=C(C3=C(C(F)(F)F)C=C(NC(=N)N)C=C3)O2)C(C(F)(F)F)=C1 CQIACFJXPBKTCI-UHFFFAOYSA-N 0.000 description 4
- IFKOKKYJMCJYSF-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)O2)C=C1 Chemical compound N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)O2)C=C1 IFKOKKYJMCJYSF-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- RTSOJVJDKNKNFU-UHFFFAOYSA-N 5-(4-nitrophenyl)furan-2-carbaldehyde Chemical compound C1=CC([N+](=O)[O-])=CC=C1C1=CC=C(C=O)O1 RTSOJVJDKNKNFU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- RGEKQCLJQHCVQH-UHFFFAOYSA-N CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)S1 Chemical compound CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)S1 RGEKQCLJQHCVQH-UHFFFAOYSA-N 0.000 description 3
- UTNIUXLNOKNKGA-UHFFFAOYSA-N COC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(OC)C=C(NC(=N)N)C=C2)O1 Chemical compound COC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(OC)C=C(NC(=N)N)C=C2)O1 UTNIUXLNOKNKGA-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 description 3
- 108010079944 Interferon-alpha2b Proteins 0.000 description 3
- KXYFVRANUDNVOI-UHFFFAOYSA-N N=C(N)C1=CC=C(C2=CC=C(C3=CC(C(=N)N)=CC=C3)N2)C=C1 Chemical compound N=C(N)C1=CC=C(C2=CC=C(C3=CC(C(=N)N)=CC=C3)N2)C=C1 KXYFVRANUDNVOI-UHFFFAOYSA-N 0.000 description 3
- SEUQKSILENGZBY-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CC=C(C3=C(Cl)C=C(NC(=N)N)C=C3)O2)C(Cl)=C1 Chemical compound N=C(N)NC1=CC=C(C2=CC=C(C3=C(Cl)C=C(NC(=N)N)C=C3)O2)C(Cl)=C1 SEUQKSILENGZBY-UHFFFAOYSA-N 0.000 description 3
- SJHJGLPARRTXCQ-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)S2)C=C1 Chemical compound N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)S2)C=C1 SJHJGLPARRTXCQ-UHFFFAOYSA-N 0.000 description 3
- ABNPBCZOCCMUEE-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CC=C(C3=CC=CC(NC(=N)N)=C3)O2)C=C1 Chemical compound N=C(N)NC1=CC=C(C2=CC=C(C3=CC=CC(NC(=N)N)=C3)O2)C=C1 ABNPBCZOCCMUEE-UHFFFAOYSA-N 0.000 description 3
- QFCZROVLRHSRHU-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=COC(C3=CC=C(NC(=N)N)C=C3)=C2)C=C1 Chemical compound N=C(N)NC1=CC=C(C2=COC(C3=CC=C(NC(=N)N)C=C3)=C2)C=C1 QFCZROVLRHSRHU-UHFFFAOYSA-N 0.000 description 3
- UGYFEHSCARCWND-UHFFFAOYSA-N N=C(N)NC1=CC=C(C2=CSC(C3=CC=C(NC(=N)N)C=C3)=N2)C=C1 Chemical compound N=C(N)NC1=CC=C(C2=CSC(C3=CC=C(NC(=N)N)C=C3)=N2)C=C1 UGYFEHSCARCWND-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229940035024 thioglycerol Drugs 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- HNKNQFPHXUOLQW-UHFFFAOYSA-N 2,5-bis(4-nitrophenyl)furan Chemical class C1=CC([N+](=O)[O-])=CC=C1C1=CC=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 HNKNQFPHXUOLQW-UHFFFAOYSA-N 0.000 description 2
- XVCKLKOCOZODJP-UHFFFAOYSA-N 2-[4-[5-[4-(diaminomethylideneamino)-2,6-dimethylphenyl]furan-2-yl]-3,5-dimethylphenyl]guanidine;dihydrochloride Chemical compound Cl.Cl.CC1=CC(NC(N)=N)=CC(C)=C1C1=CC=C(C=2C(=CC(NC(N)=N)=CC=2C)C)O1 XVCKLKOCOZODJP-UHFFFAOYSA-N 0.000 description 2
- XBMRXNGPOPXNQZ-UHFFFAOYSA-N 4-[5-(4-amino-2-methoxyphenyl)furan-2-yl]-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1C1=CC=C(C=2C(=CC(N)=CC=2)OC)O1 XBMRXNGPOPXNQZ-UHFFFAOYSA-N 0.000 description 2
- IEHABTGUFDPZLD-UHFFFAOYSA-N 4-[5-(4-aminophenyl)furan-2-yl]aniline Chemical class C1=CC(N)=CC=C1C1=CC=C(C=2C=CC(N)=CC=2)O1 IEHABTGUFDPZLD-UHFFFAOYSA-N 0.000 description 2
- YJLOMWPGACWMQP-UHFFFAOYSA-N 4-[5-[4-amino-2-(trifluoromethyl)phenyl]furan-2-yl]-3-(trifluoromethyl)aniline Chemical compound FC(F)(F)C1=CC(N)=CC=C1C1=CC=C(C=2C(=CC(N)=CC=2)C(F)(F)F)O1 YJLOMWPGACWMQP-UHFFFAOYSA-N 0.000 description 2
- ZYRMDDPFSZKNFM-UHFFFAOYSA-N C.Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 Chemical compound C.Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 ZYRMDDPFSZKNFM-UHFFFAOYSA-N 0.000 description 2
- XDFQDDCYYZDDDY-UHFFFAOYSA-N C1=CC2=C(C=C1)N/C(C1=CC=C(C3=CC=C(C4=NCCN4)C=C3)O1)=N\2 Chemical compound C1=CC2=C(C=C1)N/C(C1=CC=C(C3=CC=C(C4=NCCN4)C=C3)O1)=N\2 XDFQDDCYYZDDDY-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZVJRSUNJJCKFPT-UHFFFAOYSA-N CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc([N+](=O)[O-])cc3)O1)N2 Chemical compound CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc([N+](=O)[O-])cc3)O1)N2 ZVJRSUNJJCKFPT-UHFFFAOYSA-N 0.000 description 2
- GLHDQWIDLIBEJW-UHFFFAOYSA-N CCCCCCNC(C)=N Chemical compound CCCCCCNC(C)=N GLHDQWIDLIBEJW-UHFFFAOYSA-N 0.000 description 2
- XGHGQUFNSROKMB-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1 Chemical compound COC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1 XGHGQUFNSROKMB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000710778 Pestivirus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ZNGPPGHYHNRAEZ-UHFFFAOYSA-N furan;dihydrochloride Chemical compound Cl.Cl.C=1C=COC=1 ZNGPPGHYHNRAEZ-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000011999 immunoperoxidase monolayer assay Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VPWFNCFRPQFWGS-UHFFFAOYSA-N tert-butyl n-[amino-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical class CC(C)(C)OC(=O)NC(N)=NC(=O)OC(C)(C)C VPWFNCFRPQFWGS-UHFFFAOYSA-N 0.000 description 2
- 230000014599 transmission of virus Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- XITPERBRJNUFSB-BVBGJJFLSA-N (2s)-2-[[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 XITPERBRJNUFSB-BVBGJJFLSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HIMGPQVBNICCGL-UHFFFAOYSA-N 1-bromo-2-methyl-4-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=CC=C1Br HIMGPQVBNICCGL-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- OIPDBTSFMNBQLO-UHFFFAOYSA-N 2,5-bis(2,6-dimethyl-4-nitrophenyl)furan Chemical compound CC1=CC([N+]([O-])=O)=CC(C)=C1C1=CC=C(C=2C(=CC(=CC=2C)[N+]([O-])=O)C)O1 OIPDBTSFMNBQLO-UHFFFAOYSA-N 0.000 description 1
- AOOOFPJWUPWFNE-UHFFFAOYSA-N 2,5-bis(2-chloro-4-nitrophenyl)furan Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1C1=CC=C(C=2C(=CC(=CC=2)[N+]([O-])=O)Cl)O1 AOOOFPJWUPWFNE-UHFFFAOYSA-N 0.000 description 1
- PUVJCLKSEACSHA-UHFFFAOYSA-N 2,5-bis(2-methoxy-4-nitrophenyl)furan Chemical compound COC1=CC([N+]([O-])=O)=CC=C1C1=CC=C(C=2C(=CC(=CC=2)[N+]([O-])=O)OC)O1 PUVJCLKSEACSHA-UHFFFAOYSA-N 0.000 description 1
- XXXUICGUUHWVLE-UHFFFAOYSA-N 2,5-bis(2-methyl-4-nitrophenyl)furan Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C1=CC=C(C=2C(=CC(=CC=2)[N+]([O-])=O)C)O1 XXXUICGUUHWVLE-UHFFFAOYSA-N 0.000 description 1
- JTDGPFYEZOPGEL-UHFFFAOYSA-N 2,5-bis[4-nitro-2-(trifluoromethyl)phenyl]furan Chemical compound FC(F)(F)C1=CC([N+](=O)[O-])=CC=C1C1=CC=C(C=2C(=CC(=CC=2)[N+]([O-])=O)C(F)(F)F)O1 JTDGPFYEZOPGEL-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- PSWDQTMAUUQILQ-UHFFFAOYSA-N 2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound N1=C(C)C2=CC(OC)=CC=C2N=C1NC1=NC(=O)C(C)=C(C)N1 PSWDQTMAUUQILQ-UHFFFAOYSA-N 0.000 description 1
- JGMXNNSYEFOBHQ-OWOJBTEDSA-N 2-[(e)-4-morpholin-4-ylbut-2-enyl]-1,1-dioxothieno[3,2-e]thiazine-6-sulfonamide Chemical compound O=S1(=O)C=2SC(S(=O)(=O)N)=CC=2C=CN1C\C=C\CN1CCOCC1 JGMXNNSYEFOBHQ-OWOJBTEDSA-N 0.000 description 1
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 1
- VUWBCGMLQXSRAR-UHFFFAOYSA-N 2-[3-chloro-4-[5-[2-chloro-4-(diaminomethylideneamino)phenyl]furan-2-yl]phenyl]guanidine;dihydrochloride Chemical compound Cl.Cl.ClC1=CC(NC(=N)N)=CC=C1C1=CC=C(C=2C(=CC(NC(N)=N)=CC=2)Cl)O1 VUWBCGMLQXSRAR-UHFFFAOYSA-N 0.000 description 1
- VYPZXRPHZQZVSR-UHFFFAOYSA-N 2-[4-[5-[4-(diaminomethylideneamino)-2-methoxyphenyl]furan-2-yl]-3-methoxyphenyl]guanidine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(NC(N)=N)=CC=C1C1=CC=C(C=2C(=CC(NC(N)=N)=CC=2)OC)O1 VYPZXRPHZQZVSR-UHFFFAOYSA-N 0.000 description 1
- RHQFMXKFOLAMTJ-UHFFFAOYSA-N 2-[4-[5-[4-(diaminomethylideneamino)-2-methylphenyl]furan-2-yl]-3-methylphenyl]guanidine;dihydrochloride Chemical compound Cl.Cl.CC1=CC(NC(N)=N)=CC=C1C1=CC=C(C=2C(=CC(NC(N)=N)=CC=2)C)O1 RHQFMXKFOLAMTJ-UHFFFAOYSA-N 0.000 description 1
- AMKZOIRKLNOPMP-UHFFFAOYSA-N 2-[4-[5-[4-(diaminomethylideneamino)phenyl]furan-2-yl]phenyl]guanidine;dihydrochloride Chemical compound Cl.Cl.C1=CC(NC(=N)N)=CC=C1C1=CC=C(C=2C=CC(NC(N)=N)=CC=2)O1 AMKZOIRKLNOPMP-UHFFFAOYSA-N 0.000 description 1
- MDIUQZPRHOZKMG-UHFFFAOYSA-N 2-bromo-1,3-dimethyl-5-nitrobenzene Chemical compound CC1=CC([N+]([O-])=O)=CC(C)=C1Br MDIUQZPRHOZKMG-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- YQQCEOMFCLGSTF-UHFFFAOYSA-N 3,4-diaminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C(N)=C1 YQQCEOMFCLGSTF-UHFFFAOYSA-N 0.000 description 1
- ASHZICUITQEMNI-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-4-[5-[2-(1h-benzimidazol-2-yl)-4-carbamimidoylphenyl]furan-2-yl]benzenecarboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC=C2NC(C=3C(C=4OC(=CC=4)C=4C(=CC(=CC=4)C(N)=N)C=4NC5=CC=CC=C5N=4)=CC=C(C=3)C(=N)N)=NC2=C1 ASHZICUITQEMNI-UHFFFAOYSA-N 0.000 description 1
- YOXZIATXJWIEOC-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-4-[5-[2-(1h-benzimidazol-2-yl)-4-cyanophenyl]furan-2-yl]benzonitrile Chemical compound C1=CC=C2NC(C=3C(C=4OC(=CC=4)C=4C(=CC(=CC=4)C#N)C=4NC5=CC=CC=C5N=4)=CC=C(C=3)C#N)=NC2=C1 YOXZIATXJWIEOC-UHFFFAOYSA-N 0.000 description 1
- OVDGUTHABMXVMI-UHFFFAOYSA-N 3-nitro-4-(propylamino)benzoic acid Chemical compound CCCNC1=CC=C(C(O)=O)C=C1[N+]([O-])=O OVDGUTHABMXVMI-UHFFFAOYSA-N 0.000 description 1
- FPOZUNXOCSBXHH-UHFFFAOYSA-N 4-(4,5-dihydroimidazol-1-yl)benzene-1,2-diamine;hydrate;hydrochloride Chemical compound O.Cl.C1=C(N)C(N)=CC=C1N1C=NCC1 FPOZUNXOCSBXHH-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- VWGLKBAOUBWFNS-UHFFFAOYSA-N 4-(5-formylfuran-2-yl)benzonitrile Chemical compound O1C(C=O)=CC=C1C1=CC=C(C#N)C=C1 VWGLKBAOUBWFNS-UHFFFAOYSA-N 0.000 description 1
- BSYROZFRIFIWKC-UHFFFAOYSA-N 4-[5-(4-amino-2,6-dimethylphenyl)furan-2-yl]-3,5-dimethylaniline Chemical compound CC1=CC(N)=CC(C)=C1C1=CC=C(C=2C(=CC(N)=CC=2C)C)O1 BSYROZFRIFIWKC-UHFFFAOYSA-N 0.000 description 1
- QSPALPKUTJGKDQ-UHFFFAOYSA-N 4-[5-(4-amino-2-chlorophenyl)furan-2-yl]-3-chloroaniline Chemical compound ClC1=CC(N)=CC=C1C1=CC=C(C=2C(=CC(N)=CC=2)Cl)O1 QSPALPKUTJGKDQ-UHFFFAOYSA-N 0.000 description 1
- BELWHGZCXXDRLR-UHFFFAOYSA-N 4-[5-(4-amino-2-methylphenyl)furan-2-yl]-3-methylaniline Chemical compound CC1=CC(N)=CC=C1C1=CC=C(C=2C(=CC(N)=CC=2)C)O1 BELWHGZCXXDRLR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ABBQHKHGWQXTJN-UHFFFAOYSA-N C1=CC2=C(C=C1)N/C(C1=CC=C(C3=CC=C(C4=NCCN4)C=C3)O1)=N\2.CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)S1.COC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(OC)C=C(NC(=N)N)C=C2)O1.N=C(N)C1=CC=C(C2=CC=C(/C3=N/C4=C(C=CC=C4)N3)O2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=C(Cl)C=C(NC(=N)N)C=C3)O2)C(Cl)=C1 Chemical compound C1=CC2=C(C=C1)N/C(C1=CC=C(C3=CC=C(C4=NCCN4)C=C3)O1)=N\2.CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)S1.COC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(OC)C=C(NC(=N)N)C=C2)O1.N=C(N)C1=CC=C(C2=CC=C(/C3=N/C4=C(C=CC=C4)N3)O2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=C(Cl)C=C(NC(=N)N)C=C3)O2)C(Cl)=C1 ABBQHKHGWQXTJN-UHFFFAOYSA-N 0.000 description 1
- WAHNZPOYMHGKDW-UHFFFAOYSA-N CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc(N)cc3)O1)N2 Chemical compound CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc(N)cc3)O1)N2 WAHNZPOYMHGKDW-UHFFFAOYSA-N 0.000 description 1
- KEGCCHOQANCTDJ-UHFFFAOYSA-N CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc(N)cc3)O1)N2.CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc([N+](=O)[O-])cc3)O1)N2.COC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1.N=C(N)C1=CC=C(C2=CC=C(C3=CC(C(=N)N)=CC=C3)N2)C=C1.Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1.O=[N+]([O-])c1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 Chemical compound CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc(N)cc3)O1)N2.CC(C)NC(N)C1=CC2=C(C=C1)/N=C(/C1=CC=C(c3ccc([N+](=O)[O-])cc3)O1)N2.COC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1.N=C(N)C1=CC=C(C2=CC=C(C3=CC(C(=N)N)=CC=C3)N2)C=C1.Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1.O=[N+]([O-])c1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 KEGCCHOQANCTDJ-UHFFFAOYSA-N 0.000 description 1
- JCBRCFAGNDPNPB-UHFFFAOYSA-N CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)O1.N=C(N)NC1=CC=C(C2=CC=C(C3=C(C(F)(F)F)C=C(NC(=N)N)C=C3)O2)C(C(F)(F)F)=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)O2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)S2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=CC(NC(=N)N)=C3)O2)C=C1.N=C(N)NC1=CC=C(C2=COC(C3=CC=C(NC(=N)N)C=C3)=C2)C=C1.N=C(N)NC1=CC=C(C2=CSC(C3=CC=C(NC(=N)N)C=C3)=N2)C=C1 Chemical compound CC1=CC(NC(=N)N)=CC=C1C1=CC=C(C2=C(C)C=C(NC(=N)N)C=C2)O1.N=C(N)NC1=CC=C(C2=CC=C(C3=C(C(F)(F)F)C=C(NC(=N)N)C=C3)O2)C(C(F)(F)F)=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)O2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=C(NC(=N)N)C=C3)S2)C=C1.N=C(N)NC1=CC=C(C2=CC=C(C3=CC=CC(NC(=N)N)=C3)O2)C=C1.N=C(N)NC1=CC=C(C2=COC(C3=CC=C(NC(=N)N)C=C3)=C2)C=C1.N=C(N)NC1=CC=C(C2=CSC(C3=CC=C(NC(=N)N)C=C3)=N2)C=C1 JCBRCFAGNDPNPB-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229940126650 Compound 3f Drugs 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241001137307 Cyprinodon variegatus Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- PALVFPPSTFTLRP-UHFFFAOYSA-N N=C(N)C1=CC=C(C2=CC=C(/C3=N/C4=C(C=CC=C4)N3)O2)C=C1 Chemical compound N=C(N)C1=CC=C(C2=CC=C(/C3=N/C4=C(C=CC=C4)N3)O2)C=C1 PALVFPPSTFTLRP-UHFFFAOYSA-N 0.000 description 1
- TZCCKCLHNUSAMQ-DUGSHLAESA-N NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N Chemical compound NC(=O)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)Cc5cccs5)C(=O)N TZCCKCLHNUSAMQ-DUGSHLAESA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- FYXMBBZORHCMDX-UHFFFAOYSA-N NOC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1 Chemical compound NOC1=CC=C(C2=CC=C(C3=CC=C(C4=NCCN4)C=C3)O2)C=C1 FYXMBBZORHCMDX-UHFFFAOYSA-N 0.000 description 1
- YPJQWUYTADSSKW-UHFFFAOYSA-N Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 Chemical compound Nc1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 YPJQWUYTADSSKW-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- RLMNYIZUGWGTHV-UHFFFAOYSA-N O=[N+]([O-])c1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 Chemical compound O=[N+]([O-])c1ccc(C2=CC=C(/C3=N/C4=C(C=C(C5=NCCN5)C=C4)N3)O2)cc1 RLMNYIZUGWGTHV-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005282 allenyl group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- KOOCFLLCMRLKGL-UHFFFAOYSA-N guanidine;dihydrochloride Chemical compound Cl.Cl.NC(N)=N.NC(N)=N KOOCFLLCMRLKGL-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006057 immunotolerant effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- LCYOCNDUEVBAAT-UHFFFAOYSA-N naphthalen-2-ylmethyl ethanimidothioate Chemical compound C1=CC=CC2=CC(CSC(=N)C)=CC=C21 LCYOCNDUEVBAAT-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- UQJXXWHAJKRDKY-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-methylsulfanylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(SC)=NC(=O)OC(C)(C)C UQJXXWHAJKRDKY-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- TWUYAXFJUMLGIN-UHFFFAOYSA-N tributyl-(5-tributylstannylfuran-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=C([Sn](CCCC)(CCCC)CCCC)O1 TWUYAXFJUMLGIN-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- This invention relates to the treatment of bovine viral diarrhea virus (BVDV) and hepatitis C virus (HCV) infections.
- BVDV bovine viral diarrhea virus
- HCV hepatitis C virus
- Bovine viral diarrhea virus is an enveloped, single-stranded, positive sense RNA virus in the genus Pestivirus and the family Flaviviridae. Based on the presence or absence of visible cytopathic effect when susceptible cell monolayers are infected, two pathogenic biotypes of BVDV, referred to as cytopathic and noncytopathic, have been identified. Perdrizet J A in: B. P. Smith (ed), Large Animal Internal Medicine, First Edition (Mosby Press, St Louis, 731-737 (1990)). A differentiation is also made between biotypes of BVDV (referred to as biotypes I and II) based on certain viral RNA sequences in the 5′ untranslated region of the genome. Pellerin C, et al., Virology 203, 260-268 (1994); J. F. Ridpath et al., Virology 205, 66-74 (1994).
- BVDV may cause acute infection in cattle, resulting in bovine respiratory disease, diarrhea and severe reproductive losses. Clinical symptoms of acute BVDV infection may range from the almost undetectable to the severe. Infection of pregnant cows and heifers may result in breeding problems (e.g., irregular heats), abortion, premature births or the birth of weak or stunted calves. In some cases, temporary damage to an animal's immune system may occur even when the clinical symptoms are not apparent. In addition to the illness caused by the virus itself, infected animals are more susceptible and are more likely to suffer from other diseases, such as pneumonia.
- BVDV may also establish persistent infections. Potgieter, Vet. Clin. North Am. Food Anim. Pract 11, 501-520 (1995). Persistent BVDV infections are generally established via in utero infection of a developing fetus with a noncytopathic BVDV. The resulting animals are born immunotolerant of the particular BVDV by which they are infected, and may continually shed virus throughout their life span. While some persistently infected animals exhibit congenital malformations due to BVDV infection, many animals persistently infected with BVDV appear clinically normal. Baker, Rev. Sci. Tech 9, 25-41 (1990); Bielefeldt-Ohmann, Vet. Clin. North Am. Food Anim. Pract 11, 447-476 (1995). Persistently infected animals are thought to be the major disseminators of BVDV in the cattle population.
- BVDV can be introduced into the embryo production system in association with gametes, serum, somatic cells, cumulus oocyte complexes (COCs), and result in contaminated in vitro fertilized (IVF) embryos or cell lines.
- COCs cumulus oocyte complexes
- IVF in vitro fertilized embryos or cell lines.
- HCV hepatitis C virus
- liver failure due to HCV is the presently the leading cause of liver transplants in the United States. It is suspected that there are, at present, more than 5 million people in the United States that are infected with HCV, and perhaps as many as 200 million around the world, making HCV infection a significant public health threat.
- the nucleotide analog ribavirin (VIRAZOLE®/ICN Pharmaceuticals) has been shown to reduce concentrations of hepatitis C viral RNA in an infected subject, although at a slower rate than interferon alpha-2b. As with BVDV infection, a need exists for an effective treatment for HCV infection.
- one aspect of the invention relates to novel compounds that are useful in treating members of the Flaviviridae family of viruses, such as bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection.
- BVDV bovine viral diarrhea virus
- HCV hepatitis C virus
- Compounds of the present invention will have a structure according to Formulas (I)-(VI), as follows:
- X 1 and X 3 are each independently selected from the group consisting of O, S and NR 9 , wherein R 9 is H or alkyl;
- X 2 and X 4 are each independently CH or N;
- A is selected from the group consisting of H, alkyl, aryl,
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of H, alkyl, alkoxy, amidine, halide, alkylhalide, nitro and amino groups;
- R 6 is H, alkyl or aryl
- R 7 and R 8 are each independently selected from the group consisting of H and alkyl.
- compositions comprising a compound having a structure according to Formulas (I)-(VI), or a pharmaceutical salt thereof (i.e., an “active compound”), in a pharmaceutically acceptable carrier.
- Pharmaceutical compositions of the present invention are useful in the treatment of bovine viral disease virus (BVDV) infection and hepatitis C virus (HCV) infection.
- BVDV bovine viral disease virus
- HCV hepatitis C virus
- Certain aspects of the invention relate to methods of treating bovine viral disease virus (BVDV) infection in a subject in need of such treatment.
- the method comprises administering to the subject a compound according to Formulas (I) through (VI), or a pharmaceutically acceptable salt thereof, in an amount effective to treat bovine viral disease virus (BVDV) infection.
- HCV hepatitis C virus
- the method comprises administering to the subject a compound according to Formulas (I) through (VI), or a pharmaceutically acceptable salt thereof, in an amount effective to treat hepatitis C virus (HCV) infection.
- a further aspect of the present invention is the use of the active compounds described herein for the manufacture of a medicament for the treatment of bovine viral disease virus (BVDV) infection in a subject in need of such treatment.
- BVDV bovine viral disease virus
- Still another aspect of the present invention is the use of the active compounds described herein for the manufacture of a medicament for the treatment of treating hepatitis C virus (HCV) infection in a subject in need of such treatment.
- HCV hepatitis C virus
- FIG. 1 illustrates four chemical schemes useful in the synthesis of compounds of the present invention.
- alkyl refers to C1-10 inclusive, linear, branched, or cyclic, saturated or unsaturated (i.e., alkenyl and alkynyl) hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups.
- alkyl specifically includes cycloakyl hydrocarbon chains, which as used herein refers to C3 to C6 cyclic alkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. In the present invention, preferred alkyls are the lower alkyls.
- lower alkyl refers to C1 to C4 linear or branched alkyl, such as methyl, ethyl, propyl, butyl, isopropyl, sec-butyl, and tert-butyl.
- alkyl also encompasses substituted alkyls, which include aminoalkyls, hydroalkyls, oxygen-substituted alkyls (i.e., alkoxy groups), and halogen-substituted alkyls (i.e., alkyl halides, polyhaloalkyls).
- aminoalkyl refers to C1 to C4 linear or branched amino-substituted alkyl, wherein the term “amino” refers to the group NR′R′′, and wherein R′ and R′′ are independently selected from H or lower alkyl as defined above, i.e., —NH 2 , —NHCH 3 , —N(CH 3 )2, etc.
- hydroxyalkyl refers to C1 to C4 linear or branched hydroxy-substituted alkyl, i.e., —CH 2 OH, —(CH 2 ) 2 OH, etc.
- alkoxy refers to C1 to C4 oxygen-substituted alkyl, i.e., —OCH 3 .
- loweralkoxy refers to C1 to C4 linear or branched alkoxy, such as methoxy, ethoxy, propyloxy, butyloxy, isopropyloxy, and t-butyloxy.
- halo and halide have their conventional meaning and refer to fluoro, chloro, bromo, and iodo groups. Preferred halo groups include chloro groups, and preferred alkyl halides of the present invention include CF 3 . “Nitro” groups, as used herein, have the structure —NO 2 .
- aryl refers to C3 to C10 cyclic aromatic groups such as phenyl, naphthyl, and the like, and specifically includes substituted aryl groups including but not limited to tolyl, substituted phenyl, and substituted naphthyl.
- Aryl groups may be substituted with halo, amino, nitro, and the like.
- aryl Heterocyclic aromatic rings and polycyclic aromatic groups are also included in this definition of “aryl.” Specific examples of aryl groups encompassed by the present invention include but are not limited to cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, isothiazole, isoxazole, pyrazole, pyrazine, pyrimidine, and the like.
- the compounds of the present invention are also useful in the form of their pharmaceutically acceptable salt forms.
- Such salts may include, but are not limited to, the gluconate, lactate, acetate, tartarate, citrate, phosphate, borate, nitrate, sulfate, hydrobromide and hydrochloric salts of the compounds.
- Compounds of Formulas (I)-(VI) and their pharmaceutically acceptable salts are referred to herein as “active compounds” or “active agents.”
- the compounds represented by the Formulas (I) through (VI) may be formed by synthesis procedures that are described in the Examples below, as well as by certain methods known in the art. Some of these known methods are set forth below in the Examples by description or by reference (the disclosures of which are all incorporated herein by reference in their entirety).
- bovine viral diarrhea virus infection means any infection (e.g., acute, latent or persistent) caused by a virus classified as a bovine viral disease virus (BVDV).
- BVDV is an enveloped, single-stranded, positive sense RNA virus in the genus Pestivirus and the family Flaviviridae.
- bovine viral disease virus (BVDV) encompasses all BVDV strains and all serotypes and variants thereof, including live, attenuated, killed or otherwise inactivated forms.
- BVDV specifically includes cytopathic and noncytopathic strains, and strains of both biotype I and biotype II.
- hepatitis C virus (HCV) infection includes any infections caused by the hepatitis C virus (HCV), which includes all strains, serotypes and variants of HCV.
- a subject is administered a therapeutically-effective amount of the compound of formulas (I) through (VI), or a pharmaceutically acceptable salt thereof.
- a “therapeutically-effective” amount as used herein is an amount of a compound of formulas (I) through (VI) that is sufficient to alleviate (e.g., mitigate, decrease, reduce) at least one of the symptoms associated with BVDV or HCV infection. It is not necessary that the administration of the compound eliminate the symptoms of BVDV or HCV, as long as the benefits of administration of compound outweigh the detriments.
- BVDV and HCV are not intended to mean that the avian subject is necessarily cured of BVDV or HCV, or that all clinical signs thereof are eliminated, only that some alleviation or improvement in the condition of the subject is effected by administration of the compound of Formulas (I) through (VI).
- Suitable subjects of the present invention include humans and animals.
- mammals are preferred, with livestock (e.g., cattle, pigs, sheep, horses) and primates (e.g., monkeys, apes) being particularly preferred.
- bovine subjects e.g., cows, bulls, calves
- HCV infections humans are the preferred subjects.
- Subjects may be adult, adolescent, juvenile, infant, or neonatal.
- the subject is a live embryo, and may be in utero or in vitro (in the case of an embryo being maintained for in vitro fertilization).
- Subjects may be administered the compounds and compositions of the present invention by any suitable means.
- exemplary means are oral administration (e.g., in the form of a liquid or solid), intramuscular injection, subcutaneous injection, and intravenous injection.
- Pharmaceutical formulations of the present invention comprise active compounds of the invention in a pharmaceutically acceptable carrier. Suitable pharmaceutical formulations include those suitable for inhalation, oral, rectal, topical, (including buccal, sublingual, dermal, vaginal and intraocular), parenteral (including subcutaneous, intradermal, intramuscular, intravenous and intraarticular) and transdermal administration.
- the most suitable route of administration in any given case may depend upon the anatomic location of the condition being treated in the subject, the nature and severity of the condition being treated, and the particular active compound which is being used.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art.
- the compounds may be administered to the embryo by adding the active compound, in a suitable concentration, to the medium in which the embryo is being obtained.
- active compounds or the pharmaceutically acceptable salts thereof are typically admixed with, inter alia, an acceptable carrier.
- the carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient.
- the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.5% to 99% by weight of the active compound.
- One or more active compounds may be incorporated in the formulations of the invention, which formulations may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory therapeutic ingredients.
- Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
- Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above).
- the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture.
- a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s).
- Molded tablets may be made by molding, in a suitable machine, the powdered compound moistened with an inert liquid binder.
- Formulations for oral administration may optionally include enteric coatings known in the art to prevent degradation of the formulation in the stomach and provide release of the drug in the small intestine.
- Formulations of the present invention suitable for parenteral administration comprise sterile aqueous and non-aqueous injection solutions of the active compound, which preparations are preferably isotonic with the blood of the intended recipient. These preparations may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
- Aqueous and non-aqueous sterile suspensions may include suspending agents and thickening agents.
- the formulations may be presented in unit ⁇ dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or water-for-injection immediately prior to use.
- sterile liquid carrier for example, saline or water-for-injection immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- an injectable, stable, sterile composition comprising a compound of Formula (I)-Formula (VI), or a salt thereof, in a unit dosage form in a sealed container.
- the compound or salt is provided in the form of a lyophilizate which is capable of being reconstituted with a suitable pharmaceutically acceptable carrier to form a liquid composition suitable for injection thereof into a subject.
- the unit dosage form typically comprises from about 10 mg to about 10 grams of the compound or salt.
- a sufficient amount of emulsifying agent which is physiologically acceptable may be employed in sufficient quantity to emulsify the compound or salt in an aqueous carrier.
- the present invention provides liposomal formulations of the compounds disclosed herein and salts thereof.
- the technology for forming liposomal suspensions is well known in the art.
- the compound or salt thereof is an aqueous-soluble salt, using conventional liposome technology, the same may be incorporated into lipid vesicles. In such an instance, due to the water solubility of the compound or salt, the compound or salt will be substantially entrained within the hydrophilic center or core of the liposomes.
- the lipid layer employed may be of any conventional composition and may either contain cholesterol or may be cholesterol-free.
- the salt may be substantially entrained within the hydrophobic lipid bilayer which forms the structure of the liposome.
- the liposomes which are produced may be reduced in size, as through the use of standard sonication and homogenization techniques.
- the liposomal formulations containing the pharmaceutically active compounds identified with the methods described herein may be lyophilized to produce a lyophilizate which may be reconstituted with a pharmaceutically acceptable carrier, such as water, to regenerate a liposomal suspension.
- the pharmaceutical formulations may contain other additives, such as pH-adjusting additives.
- useful pH-adjusting agents include acids, such as hydrochloric acid, bases or buffers, such as sodium lactate, sodium acetate, sodium phosphate, sodium citrate, sodium borate, or sodium gluconate.
- the compositions may contain microbial preservatives.
- Useful microbial preservatives include methylparaben, propylparaben, and benzyl alcohol. The microbial preservative is typically employed when the formulation is placed in a vial designed for multidose use.
- the pharmaceutical formulations of the present invention may be lyophilized using techniques well known in the art.
- compositions of the present invention may comprise compounds of the present invention in lyophilized form.
- pharmaceutical formulations of the present invention may comprise compounds of the present invention in a pharmaceutically acceptable carrier.
- Such pharmaceutical formulations are generally made by admixing the compounds described herein with a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers are preferably liquid, particularly aqueous, carriers, the selection of which are known in the art.
- the compound may be mixed in a buffered saline (e.g., pH 6 to 8) or conventional culture media.
- the formulation may be stored in a sterile glass container sealed with a rubber stopper through which liquids may be injected and formulation withdrawn by syringe.
- a therapeutically effective dosage of any specific compound may vary somewhat from compound to compound and subject to subject, and will depend upon the condition of the subject and the route of delivery.
- a dosage from about 1 mg/kg to about 15 mg/kg of subject body weight, or about 20 mg/kg of subject body weight, or even about 25 mg/kg of subject body weight may be employed for intravenous injection or oral administration.
- concentration of the compound of the present invention or a pharmaceutically acceptable salt thereof in a formulation of the present invention may be determined by the skilled artisan and will vary according to certain conditions, including the characteristics of subject being treated (e.g., species, age, weight), the severity and type of the infecting virus or the strain that the subject is being vaccinated against, the dosage form being used, and the like.
- the compounds of the present invention may be administered in conjunction with other antiviral compounds, as may be determined by the skilled artisan.
- compound numbers refer to compounds with structures that are set forth in FIG. 1.
- the mono salt (0.65 g) was dissolved in 120 ml of ethanol and acidified with HCl-saturated ethanol and after standing overnight in a refrigerator the resultant solid was filtered, washed with ether and dried for 24 h in a vacuum oven at 70° C. to yield 0.6 g (85%) mp 300° C.
- the mono salt was dissolved in 100 ml of ethanol and acidified with HCl-saturated ethanol and after cooling in an ice bath the resultant solid was filtered, washed with ether and dried for 24 h in a vacuum oven at 75° C. to yield 0.7 g (91%) mp>300° C.
- MEM-eq minimum essential medium (MEM) with Earle's salts supplemented with 10% (v/v) equine serum, sodium bicarbonate (0.75 mg/ml), L-glutamine (0.29 mg/ml), penicillin G (100 U/ml), streptomycin (100 ⁇ g/ml), and amphotericin B (0.25 ⁇ g/ml)), which was derived by trypsinization of a confluent monolayer of Madin Darby Bovine Kidney (MDBK) cells in a 25 cm 2 flask. Cells were incubated at 38.5° C. with 5% CO 2 for 24 hours. The average number of cells per well was determined and later used to calculate appropriate multiplicities of infection (MOI) of BVDV virus.
- MEM-eq minimum essential medium
- MDBK Madin Darby Bovine Kidney
- the MDBK cells were resuspended in MEM-eq with no antiviral compound.
- Uterine tubal cells (UTC) were freeze-thawed and stored at ⁇ 80° C. for analysis.
- UTC lysates were serially diluted with medium from Day 7 and assayed by immunoperoxidase for the presence of BVDV.
- peroxidase-conjugated rabbit anti-mouse IgG (Jackson Immuno Research Lab, West Grove, Pa.) was added. After a short incubation period, unbound peroxidase-conjugated antibody was removed by washing with PBS and Tween 20. Finally, the enzyme substrate, aminoethyl carbazole (Zymed Laboratories, Inc., South San Francisco, Calif.), which produces a reddish-brown color when oxidized by horseradish peroxidase, was added. Color change was visualized under light microscopy and compared to known positive and negative controls on each plate.
- RNA samples were stored at ⁇ 80° C. until RT-nPCR was performed.
- the initial reverse transcription polymerase chain reaction was performed in the bottom of the tubes containing the dried trehalose mixture within the lid.
- Two ⁇ L of RNA were added through the overlaid mineral oil (50 ⁇ L) to the initial reaction volume (48 ⁇ L) containing the following reagents (Promega): 5 ⁇ L 10 ⁇ buffer, 8 ⁇ L of MgCl2 (25 mM), 2 ⁇ L of dNTPs (10 mM), 1 ⁇ L of each outer primer BVD 100 and HCV 368 (5 ⁇ M), 1 ⁇ L of Triton X-100 (10% stock), 0.25 ⁇ L of dithiothreitol (100 mM), 0.25 ⁇ L (10 U) RNAsin, 0.5 ⁇ L (2.5 U) of Taq polymerase, and 0.5 ⁇ L (100 U) of MMLV (Moloney Murine Leukemia Virus) reverse transcriptase.
- the tubes were then subjected to the following reagent
- a final elongation step of 72° C. for 10 min completed the initial amplification reaction.
- the tubes were inverted several times to mix the samples in the lid and in the base to initiate the nested polymerase chain reaction (nPCR).
- the tubes were then centrifuged at 14,000 ⁇ g for 12 sec before returning to the thermocycler for nPCR, using 30 cycles of 94° C. for 1 min, 55° C. for 1 min and 72° C. for 45 sec.
- a final elongation step of 72° C. for 10 min completed the amplification process prior to maintaining the reactions at 4° C.
- Five microliter aliquots of PCR products were separated by 1.5% agarose gel electrophoresis.
- the agarose gels contained 0.5 ⁇ g/ml ethidium bromide to allow visualization of RT-nPCR products using an ultraviolet transilluminator.
- the outer primers, BVD 100 (5′-GGCTAGCCATGCCCTTAG-3′) (SEQ ID NO. 1) and HCV 368 (5′-CCATGTGCCATGTACAG-3′) (SEQ ID NO. 2) amplified a 290 base pair sequence of the 5′ untranslated region of the viral genome.
- the inner primers, BVD 180 (5′-CCTGAGTACAGGGDAGT CGTCA-3′) (SEQ ID NO. 3) and HCV 368 amplified a 213 base pair sequence within the first amplicon.
- Cow ovaries were collected at an abattoir in Omaha, Neb., and placed in PBS for transport to a nearby laboratory.
- the contents of 1- to 10-mm follicles were aspirated at a vacuum rate of 21.5 ml/min and poured onto a 70 ⁇ m filter.
- Cellular components of the pooled follicular aspirate were rinsed with TL-HEPES and searched for oocytes surrounded by multiple layers of dense cumulus cells.
- Useable cumulus oocyte complexes (COCs) were washed two additional times in TL-HEPES, then placed in 7.5 ml of maturation media that had previously equilibrated at 38.5° C. in an atmosphere of 5% CO 2 and humidified air. The maturation media was then sealed and maintained at 38.5° C. for 20 to 22 h while being transported to the experimental laboratory.
- Oocytes were matured in cell culture medium 199 (CCM 199) with Earle's salts (GIBCO-BRL, Grand Island, N.Y., USA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; HyClone Lab., Inc., Logan, Utah, USA), sodium pyruvate (11 ⁇ g/ml), bovine FSH (0.01 U/ml), bovine LH (0.01 U/ml), penicillin (100 U/ml) and streptomycin (100 ⁇ g/ml).
- Matured oocytes were fertilized in CR2 medium (C. F. Rosenkrans et al., Theriogenology 35, 266 (1991)) supplemented with BSA (6 mg/ml), heparin (10 ⁇ g/ml), penicillamine (0.3 ⁇ g/ml), hypotaurine (0.2 ⁇ g/ml), penicillin (100 ⁇ /ml) and streptomycin (100 ⁇ g/ml).
- IVC in vitro culture
- BVDV Bovine Viral Diarrhea Virus
- the noncytopathic strains of BVDV used in this research included 2 diverse Genotype I strains (SD-1 and NY-1) and 2 diverse Genotype II strains (CD-87 and PA-131). Givens M D et al., Theriogenology 2000;54:1093-1107. All stocks were propagated in BVDV-free MDBK cells cultured in MEM-eq. Virus was harvested by freezing and thawing and was stored in cryovials at ⁇ 80° C. until needed.
- the nearly nude embryos were examined for cleavage, and those at the 5-cell stage or greater were washed 1 more time in IVC medium and placed with pieces of detached cumulus in 60- ⁇ l drops (20 to 25 per drop) of the IVC medium with 10% (v/v) FBS under mineral oil. These developed embryos were incubated an additional 4 d. After the final 4 d in IVC, embryos were transferred into 3 ml of MEM-eq, separated from cumulus cells, and development to the morula or blastocyst stage was noted.
- tissue culture infective dose 50% (TCID 50 )/ml of the exposure aliquot was determined by the method of Reed and Muench (L. J. Reed and H. Muench, Am J Hygiene 27, 493-497 (1938). Results of viral detection assays were compared using a Pearson Chi-square test statistic (J. Sall and A. Lehman, JMP Start Statistics (Duxbury Press, Belmont, Calif. (1996),195-211).
- Table 2 sets forth the results of the analysis of in vitro culture media and cell lysates that have been treated with the indicated antiviral compound for the indicated time at a concentration of 12.5 ⁇ M, after exposure to BVDV at a MOI of 0.05 (see Example 12).
- Table 3 sets forth the results of the analysis of in vitro culture media and cell lysates that have been treated with the indicated antiviral compound for the indicated time at a concentration of 12.5 ⁇ M, after exposure to BVDV at a MOI of 1.0 (see Example 12).
- Table 4 sets forth the results of the analysis of Day 3 in vitro culture media and Day 3 cell lysate that has been treated with the indicated antiviral compound at a concentration of 12.5 ⁇ M, after exposure to BVDV at a MOI of 0.5 (see Example 12).
- Table 5 sets forth the results of the analysis of Day 3 cell lysates that have been treated with the indicated antiviral compound for three days at the indicated concentration, after exposure to BVDV at a MOI of 0.05.
- TABLE 5 Day 3 Media Day 3 Cell Lysates Antiviral drug TCID 50 /mL % Control TCID 50 /mL % Control No antiviral 2.00E + 06 3.50E + 05 DB 456 25 ⁇ m 3.50E + 03 0.1750% 2.00E + 03 0.5714% DB 456 12 ⁇ m 6.20E + 02 0.0310% 3.50E + 03 1.0000% DB 456 6 ⁇ m 3.50E + 04 1.7500% 3.50E + 04 10.0000% DB 456 3 ⁇ m 3.50E + 05 17.5000% 6.20E + 05 177.1429% DB 456 1.5 ⁇ m 5.10E + 05 25.5000% 3.50E + 06 1000.0000% DB 456 0.7 ⁇ m 6.30E + 05 31.500
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/044,315 US20030199521A1 (en) | 2001-01-13 | 2002-01-11 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
US10/796,657 US7183286B2 (en) | 2001-01-13 | 2004-03-09 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
US11/262,427 US7163955B2 (en) | 2001-01-13 | 2005-10-28 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
US11/601,889 US7410999B2 (en) | 2001-01-13 | 2006-11-20 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
US11/602,031 US7410989B2 (en) | 2001-01-13 | 2006-11-20 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26165401P | 2001-01-13 | 2001-01-13 | |
US10/044,315 US20030199521A1 (en) | 2001-01-13 | 2002-01-11 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/796,657 Continuation US7183286B2 (en) | 2001-01-13 | 2004-03-09 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030199521A1 true US20030199521A1 (en) | 2003-10-23 |
Family
ID=22994247
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/044,315 Abandoned US20030199521A1 (en) | 2001-01-13 | 2002-01-11 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
US10/796,657 Expired - Fee Related US7183286B2 (en) | 2001-01-13 | 2004-03-09 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/796,657 Expired - Fee Related US7183286B2 (en) | 2001-01-13 | 2004-03-09 | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
Country Status (9)
Country | Link |
---|---|
US (2) | US20030199521A1 (es) |
EP (1) | EP1399163B1 (es) |
JP (1) | JP4368582B2 (es) |
AT (1) | ATE375159T1 (es) |
AU (1) | AU2002239873B2 (es) |
CA (1) | CA2433070A1 (es) |
DE (1) | DE60222899T2 (es) |
ES (1) | ES2295316T3 (es) |
WO (1) | WO2002055025A2 (es) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040147531A1 (en) * | 2001-08-31 | 2004-07-29 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20040209823A1 (en) * | 2003-01-07 | 2004-10-21 | Benedikt Sas | Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses |
US20050158785A1 (en) * | 1999-12-20 | 2005-07-21 | The University Of North Carolina At Chapel Hill | Novel compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
US20050182118A1 (en) * | 2004-01-23 | 2005-08-18 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
EP2120952A2 (en) * | 2007-01-15 | 2009-11-25 | The United States Of America, As Represented By The Secretary of the Army, on behalf of the U.S. Army Research Institute of Infectious Diseases | Antiviral compounds and methods of using thereof |
US8865754B2 (en) | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
CN114845708A (zh) * | 2019-12-19 | 2022-08-02 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737440B2 (en) | 2000-11-06 | 2004-05-18 | The University Of North Carolina At Chapel Hill | Synthesis and antimicrobial activity of novel dicationic “reversed amidines” |
AU2002246600B2 (en) * | 2000-11-06 | 2005-08-25 | Duke University | Synthesis and antimicrobial activity of novel dicationic "Reversed amidines" |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
PL374536A1 (en) | 2002-08-23 | 2005-10-31 | Rigel Pharmaceuticals, Inc. | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
US7115642B2 (en) | 2003-05-02 | 2006-10-03 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection |
EP1620412A2 (en) * | 2003-05-02 | 2006-02-01 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds and hydro isomers thereof |
US7220745B2 (en) * | 2003-05-15 | 2007-05-22 | Rigel Pharmaceuticals | Heterocyclic compounds useful to treat HCV |
WO2005049065A2 (en) | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
EG26569A (en) | 2003-12-23 | 2014-02-23 | احمد قطب عبد الله مجد | The element sulfur and its acid formations and derivatives of the enzyme deficiency of the enzyme glutase S transferfrez and epoxide hydrolys for all types of disease associated with this deficiency |
US7514434B2 (en) | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
GB0505735D0 (en) * | 2005-03-21 | 2005-04-27 | Glaxo Group Ltd | Compounds |
JP2008540425A (ja) | 2005-05-02 | 2008-11-20 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用 |
GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE620372A (es) * | 1961-07-19 | |||
GB1084175A (es) * | 1964-03-20 | |||
FR1464999A (fr) * | 1964-12-31 | 1967-01-06 | Bayer Ag | Agents éclaircissants optiques |
JPH07179856A (ja) * | 1993-12-21 | 1995-07-18 | Canon Inc | 液晶性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置 |
US5723288A (en) * | 1994-05-06 | 1998-03-03 | The University Of North Carolina At Chapel Hill | Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor |
US5602172A (en) * | 1994-05-06 | 1997-02-11 | The University Of North Carolina At Chapel Hill | Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor |
US5668165A (en) * | 1995-06-07 | 1997-09-16 | Scriptgen Pharmaceuticals, Inc. | Small molecule inhibition of RNA/ligand binding |
US6008247A (en) * | 1998-02-27 | 1999-12-28 | The University Of North Carolina At Chapel Hill | 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents |
ES2282127T3 (es) * | 1999-07-08 | 2007-10-16 | University Of North Carolina At Chapel Hill | Nuevos profarmacos para amidinas anticrobianas. |
BR0016565A (pt) * | 1999-12-20 | 2002-09-17 | Univ North Carolina | Compostos diamidina como ligantes de pequeno sulco de dna |
WO2002036588A2 (en) * | 2000-11-06 | 2002-05-10 | U.S. Army Medical Research And Materiel Command | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
US20030104473A1 (en) * | 2001-04-24 | 2003-06-05 | Qing Dong | Common ligand mimics: benzimidazoles |
KR101225018B1 (ko) * | 2004-09-02 | 2013-01-23 | 쿠리스 인코퍼레이션 | 헤지호그 신호전달에 대한 피리딜 억제제 |
-
2002
- 2002-01-11 US US10/044,315 patent/US20030199521A1/en not_active Abandoned
- 2002-01-11 WO PCT/US2002/000787 patent/WO2002055025A2/en active IP Right Grant
- 2002-01-11 EP EP02705743A patent/EP1399163B1/en not_active Expired - Lifetime
- 2002-01-11 DE DE60222899T patent/DE60222899T2/de not_active Expired - Fee Related
- 2002-01-11 AU AU2002239873A patent/AU2002239873B2/en not_active Ceased
- 2002-01-11 ES ES02705743T patent/ES2295316T3/es not_active Expired - Lifetime
- 2002-01-11 CA CA002433070A patent/CA2433070A1/en not_active Abandoned
- 2002-01-11 JP JP2002555762A patent/JP4368582B2/ja not_active Expired - Fee Related
- 2002-01-11 AT AT02705743T patent/ATE375159T1/de not_active IP Right Cessation
-
2004
- 2004-03-09 US US10/796,657 patent/US7183286B2/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050158785A1 (en) * | 1999-12-20 | 2005-07-21 | The University Of North Carolina At Chapel Hill | Novel compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
US7160914B2 (en) * | 1999-12-20 | 2007-01-09 | The University Of North Carolina At Chapel Hill | Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind in the DNA minor groove as a dimer |
US20040147531A1 (en) * | 2001-08-31 | 2004-07-29 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20040209823A1 (en) * | 2003-01-07 | 2004-10-21 | Benedikt Sas | Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses |
US7125853B2 (en) * | 2003-01-07 | 2006-10-24 | Kemin Pharma B.V.B.A. | Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses |
US20050182118A1 (en) * | 2004-01-23 | 2005-08-18 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US7262223B2 (en) | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
EP2120952A2 (en) * | 2007-01-15 | 2009-11-25 | The United States Of America, As Represented By The Secretary of the Army, on behalf of the U.S. Army Research Institute of Infectious Diseases | Antiviral compounds and methods of using thereof |
EP2120952A4 (en) * | 2007-01-15 | 2011-09-21 | Us Of America As Represented By The Secretary Of The Army On Behalf Of The U S Army Res Inst Of Infe | ANTIVIRAL COMPOUNDS AND METHOD FOR THEIR USE |
US8865754B2 (en) | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
CN114845708A (zh) * | 2019-12-19 | 2022-08-02 | 乔治亚州大学研究基金会 | 用于治疗细菌感染和增强抗生素的化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2002055025A2 (en) | 2002-07-18 |
JP2004525881A (ja) | 2004-08-26 |
ATE375159T1 (de) | 2007-10-15 |
EP1399163A4 (en) | 2005-08-31 |
ES2295316T3 (es) | 2008-04-16 |
EP1399163A2 (en) | 2004-03-24 |
AU2002239873B2 (en) | 2006-11-16 |
DE60222899D1 (de) | 2007-11-22 |
CA2433070A1 (en) | 2002-07-18 |
AU2002239873C1 (en) | 2002-07-24 |
EP1399163B1 (en) | 2007-10-10 |
US7183286B2 (en) | 2007-02-27 |
JP4368582B2 (ja) | 2009-11-18 |
US20070010533A1 (en) | 2007-01-11 |
DE60222899T2 (de) | 2008-08-14 |
WO2002055025A3 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7183286B2 (en) | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | |
AU2002239873A1 (en) | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | |
CN111494396B (zh) | 取代氨基丙酸酯类化合物在制备治疗SARS-CoV-2感染的药物中的应用 | |
US20050009775A1 (en) | Nucleoside compounds in hcv | |
US6566365B1 (en) | Method for the treatment of Flaviviridea viral infection using nucleoside analogues | |
US20080075695A1 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
CN102448458A (zh) | 治疗黄病毒科病毒感染的方法和组合物 | |
US7410999B2 (en) | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | |
JP2023512628A (ja) | SARS-CoV-2感染症の治療における安息香酸塩化合物の利用 | |
US9511070B2 (en) | Heterocyclyl carboxamides for treating viral diseases | |
JP2023534723A (ja) | コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用 | |
EP1837024A2 (en) | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection | |
KR100356443B1 (ko) | 페스티바이러스감염증및이와관련된질병의예방및치료방법 | |
CN115844879A (zh) | 褪黑素在抗盖塔病毒中的应用 | |
RU2723482C1 (ru) | Пангенотипичный ингибитор белка NS5A вируса гепатита С, фармацевтическая композиция и способы их получения и применения | |
JP2023516706A (ja) | SARS-CoV-2阻害におけるジメチルベルバミン化合物の適用 | |
JP2002524502A (ja) | ウイルス性疾患の処置法 | |
CN116003508A (zh) | 一种含氰基的硒代丁内酰胺化合物及其制备方法和用途 | |
CN113924093A (zh) | 一种肠道病毒抑制剂 | |
KR100798634B1 (ko) | C형 간염 예방 및 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STEPHENS, CHAD E.;REEL/FRAME:013168/0845 Effective date: 20020708 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL;REEL/FRAME:021062/0103 Effective date: 20031121 |